According to filings with the U.S. Securities and Exchange Commission, 9AMHEALTH is raising up to $25,696,090.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About 9AMHEALTH
9amHealth is complete cardiometabolic carea first-of-its-kind, whole-body approach to preventing and treating diabetes, obesity, high cholesterol, and hypertension. We partner with businesses looking to provide effective health benefits to their members while reducing overall healthcare costs. 9amHealth was founded in 2021 by the team behind mySugr and is backed by 7Wire Ventures, Human Capital, Founders Fund, and Define Ventures.

To learn more about 9AMHEALTH, visit https://join9am.com/
9AMHEALTH Linkedin Page: https://www.linkedin.com/company/9amhealth/

Contact:
Frank Westermann, Chief Executive Officer
202-932-9958
https://www.linkedin.com/in/frankwestermann/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.